Recent research has focused on innovative therapies aimed at regenerating corneal endothelial cells (CECs) and improving treatment outcomes for patients with corneal endothelial disorders.

In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data for the company’s cell therapy for corneal endothelial disease.

In 2022, doctors in Japan performed a transplant of iPS cell-derived corneal endothelial cells iPS cell ... including the heart, nerves and blood. In 2022, Keio University performed the world's ...

Please provide your email address to receive an email when new articles are posted on . James Funderburgh, PhD, at the University of Pittsburgh discovered stem cells in the corneal stroma in an ...

AURN001 is a combination cell therapy product candidate comprised of allogeneic human corneal endothelial cells (neltependocel) and a rho kinase inhibitor (Y-27632). AURN001 is intended to be ...